Skip to content
NIH Study: Moderna, Pfizer Injections Are Most Effective Covid Boosters


The results could present a challenge for the federal government, which has yet to recommend vaccine mixing but is expected to decide whether to give the green light to boosters for all available vaccines by the end of the month.

The Food and Drug Administration’s independent vaccine advisory group will vote this week on whether to recommend the Moderna and J&J boosters, with a decision from the agency expected shortly thereafter. The committee will also review the results of the joint study, although it is not intended to make recommendations on the approach.

The NIH study has not yet been peer reviewed. The authors recognized limitations, including that the vast majority of participants were Caucasian, and that the interval between when individuals received their primary vaccine series and their boosters was less than six months – the threshold allowed for Pfizer-BioNTech shot.

Leana Wen, an emergency physician and professor of public health at George Washington University, said the results show that mixing and pairing boosters appear to be safe and effective.

“I hope the FDA and CDC will take these results into account in their deliberations and, in particular, allow recipients of the Johnson & Johnson vaccine to receive a second dose of mRNA,” said Wen, who participated in the J&J single injection test and recommended wide availability of boosters.

Last month, the FDA cleared the emergency use of Pfizer’s vaccine as a booster for people 65 years of age and older and for people whose health conditions or jobs put them at increased risk of developing Covid severe. He could make a similar decision for Moderna this week.


Source link